OTX-2101 / Omega Therap - LARVOL DELTA

Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results (GlobeNewswire) - "The Phase 1 MYCHELANGELO trial of OTX-2002 has been completed and the Company is engaged in discussions with potential partners to further advance clinical development into Phase 2 or may choose to resume development through internal efforts with additional funding. The OTX-2101 and CXCL1-8 programs have been deprioritized in order to focus resources and capital on the three selected programs....The Company is pursuing strategic partnership opportunities to advance these programs or may choose to resume development through internal efforts with additional funding."

Pipeline update • Trial status • Solid Tumor

The Ubiquitin E3 Ligase FBXO33 Suppresses Stem Cell-Like Properties and Metastasis in Non-Small-Cell Lung Cancer by Promoting Ubiquitination and Degradation of Myc. (PubMed, Front Biosci (Landmark Ed)) - "FBXO33 is expressed at low levels in NSCLC and correlates with lower OS. Overexpression of FBXO33 promotes Myc ubiquitination and degradation and inhibits tumor cell proliferation, migration and stemness characteristics, thereby impeding NSCLC progression."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Targeted Protein Degradation

Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control (GlobeNewswire) - "Omega Therapeutics, Inc...announced the presentation of new preclinical data demonstrating the anti-tumor effect of a MYC-targeting epigenomic controller (MYC-EC) in models of EGFR inhibitor (EGFRi)-resistant non-small cell lung cancer (NSCLC) at the American Association for Cancer Research Annual Meeting 2024, taking place in San Diego, California, April 5 – 10....The combination of a MYC-directed EC (NSCLC MYC-EC) with osimertinib, a third generation EGFRi blocker, led to enhanced downregulation of MYC protein levels and synergistically inhibited viability of EGFR-T790M mutant NSCLC cells in preclinical models. NSCLC cells resistant to osimertinib through the EGFR C797S mutation or epithelial to mesenchymal transition (EMT) retained sensitivity to epigenomic downregulation of MYC expression with NSCLC MYC-EC in multiple in vitro models."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC (GlobeNewswire) - "Omega Therapeutics, Inc...announced new preclinical data supporting the potential of OTX-2101, a c-MYC-targeting epigenomic controller (MYC-EC) being developed for the treatment of non-small cell lung cancer (NSCLC), in combination with immune checkpoint inhibitors or EGFR inhibitors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics which took place in Boston, Mass., October 11 – 15, 2023....Combination of a MYC-targeting epigenomic controller (MYC-EC) with immune checkpoint or EGFR inhibitor enhanced anti-tumor activity. Treatment with a MYC-EC plus an anti-PD-L1 antibody resulted in enhanced anti-tumor activity in a syngeneic mouse model of NSCLC. Combination of MYC-EC with EGFR inhibitor, osimertinib, synergistically reduced tumor cell viability in vitro and significantly inhibited tumor growth in vivo in a human xenograft model of NSCLC."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) - "Omega Therapeutics...announced that it will present new preclinical data supporting the potential of OTX-2101, a c-MYC (MYC)-targeting epigenomic controller being developed for the treatment of non-small cell lung cancer (NSCLC), at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, Massachusetts, October 11 – 15, 2023."

Preclinical • Non Small Cell Lung Cancer

Omega Therapeutics Presents New Preclinical Data Demonstrating the Potential of Omega Epigenomic Controllers to Synergize with Immunotherapies at the ASCO 2023 Annual Meeting (GlobeNewswire) - "'We continue to advance OTX-2101 through IND-enabling studies and look forward to announcing preliminary OTX-2002 monotherapy data from our Phase 1 clinical trial this year while progressing toward initiation of the combination portion of the study'....Consistent with our previous preclinical studies, MYC OECs resulted in the downregulation of MYC mRNA and protein expression, as well as decreased cell viability in Hepa1-6 mouse liver cancer cells. MYC OECs downregulated expression of PD-L1 protein on the surface of HCC and NSCLC tumor cells in vitro. The combination of MYC OEC and anti-PD-1 or anti-PD-L1 blockade significantly reduced tumor growth in a mouse xenograft liver tumor model compared to single agent treatment."

P1 data • Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Omega Therapeutics to Present New Preclinical Data at the American Society of Clinical Oncology 2023 Annual Meeting (GlobeNewswire) - "Omega Therapeutics, Inc...announced that it will present new preclinical data related to its MYC-HCC and MYC-NSCLC programs at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois, June 2 – 6, 2023."

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer

Omega Therapeutics Unveils New Epigenomic Controller Development Candidate Targeting MYC-Driven Non-Small Cell Lung Cancer (PRNewswire) - "Omega Therapeutics, Inc...announced that it has selected OTX-2101 as the next Omega Epigenomic Controller™ (OEC) development candidate to advance into Investigational New Drug (IND)-enabling studies for the treatment of non-small cell lung cancer (NSCLC)....IND-enabling activities for OTX-2101 are underway."

Pipeline update • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor